This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End
by Zacks Equity Research
Fulcrum Therapeutics stock sinks 51% after ending pociredir development in SCD due to FDA cancer-risk concerns, leaving no clinical-stage assets.
LQDAPositive Net Change FULCPositive Net Change IMCRPositive Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Gets Opdivo Label Expansion in the EU, Update on Camzyos
by Zacks Equity Research
Bristol Myers secured EU approval for Opdivo plus AVD in newly diagnosed advanced cHL and advanced Camzyos' label expansion review.
BMYPositive Net Change LQDAPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
by Ekta Bagri
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
ILMNNegative Net Change MYGNNegative Net Change BEAMNegative Net Change PACBNegative Net Change CRSPNegative Net Change TWSTPositive Net Change
biotechnology biotechs genomics medical pharmaceuticals
Amgen Secures EU Nod for Imdylltra in Lung Cancer Indication
by Zacks Equity Research
AMGN wins EU approval for Imdylltra in extensive-stage small cell lung cancer after phase III data showed a 40% reduction in death risk.
AMGNNegative Net Change IMCRPositive Net Change INDVNegative Net Change
biotechs medical pharmaceuticals
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
by Zacks Equity Research
EWTX surges 18% to a record high after striking a $2.65 billion neuromuscular business divestiture deal with Servier, sharpening focus on its cardiovascular pipeline.
LQDAPositive Net Change IMCRPositive Net Change EWTXPositive Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Accepts Vertex's BLA for Povetacicept in IgA Nephropathy
by Zacks Equity Research
VRTX moves closer to a potential nephrology launch as the FDA accepts its BLA for povetacicept in adults with IgAN, with a decision due in November 2026.
NVSPositive Net Change VRTXNegative Net Change TVTXPositive Net Change
biotechs
FDA Grants Priority Review to Roche's Early-Stage Breast Cancer NDA
by Zacks Equity Research
RHHBY's giredestrant as an adjuvant treatment for early-stage breast cancer won FDA Priority Review, backed by encouraging phase III data versus standard therapy.
RHHBYPositive Net Change LQDAPositive Net Change IMCRPositive Net Change INDVNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
MRNA Partners With CEPI to Develop Vaccine for Bundibugyo Ebolavirus
by Zacks Equity Research
Moderna gains up to $50M from CEPI to advance a Bundibugyo ebolavirus vaccine as the partnership expands amid an ongoing Ebola outbreak.
MRNANegative Net Change IMCRPositive Net Change INDVNegative Net Change
biotechs medical pharmaceuticals vaccines
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate
by Zacks Equity Research
Agios gains global rights to cevidoplenib for ITP, adding a late-stage rare hematology asset with up to $1B U.S. peak sales potential.
AGIOPositive Net Change LQDAPositive Net Change IMCRPositive Net Change INDVNegative Net Change
biotechs
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug
by Zacks Equity Research
Replimune stock surges after the company aligned with the FDA on plans to resubmit its BLA for RP1 plus Opdivo in advanced melanoma.
BMYPositive Net Change REPLPositive Net Change LQDAPositive Net Change IMCRPositive Net Change
biotechs